---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108876"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:28:10.561627+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q2 2025 cash $296.3M; dosed first patient in SURF302 NMIBC trial

## Summary
- Cash, cash equivalents and marketable securities of $296.3M as of June 30, 2025; runway through at least 2027.
- Q2 net loss of $28.1M, vs $18.7M in Q2 2024; R&D expenses $24.3M (up from $18.0M).
- Dosed first patient in SURF302 Phase 2 study of dabogratinib for FGFR3-altered intermediate-risk NMIBC.
- BEACH301 Phase 2 achondroplasia study now enrolling safety sentinel cohort; dose first child expected 3Q 2025.
- Initial three-month complete response data from SURF302 expected in first half 2026.

## SEC filing metadata
- accession: 0000950170-25-108876
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/0000950170-25-108876-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/tyra-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108876
- JSON: https://secwatch.observer/filing/0000950170-25-108876.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108876.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.